<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>Rejoyn App by </title>
      <link>https://padlet.com/rmarsh6/rejoyn</link>
      <description>A new way of treating depression</description>
      <language>en-us</language>
      <pubDate>2024-09-22 16:00:03 UTC</pubDate>
      <lastBuildDate>2024-09-23 01:00:29 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url>https://padlet.net/icons/8.0/png/1fa7a.png</url>
      </image>
      <item>
         <title></title>
         <author>rmarsh6</author>
         <link>https://padlet.com/rmarsh6/rejoyn/wish/3131735015</link>
         <description><![CDATA[<p>Rejoyn is a prescription-based mobile app that serves as an adjunctive therapy to antidepressant medications, offering patients access to therapeutic exercises, emotional regulation training, and supportive text messages.</p>]]></description>
         <enclosure url="https://psychiatryonline.org/doi/10.1176/appi.pn.2024.06.6.15" />
         <pubDate>2024-09-22 16:21:56 UTC</pubDate>
         <guid>https://padlet.com/rmarsh6/rejoyn/wish/3131735015</guid>
      </item>
      <item>
         <title>Rejoyn app background</title>
         <author>rmarsh6</author>
         <link>https://padlet.com/rmarsh6/rejoyn/wish/3131742115</link>
         <description><![CDATA[<p>Developed by Otsuka Pharmaceutical Co. and Click Therapeutics Inc., Rejoyn is approved as an adjunctive therapy for adults aged 22 and older who are already on antidepressant medications and receiving clinician-managed outpatient care. Rejoyn was officially FDA-approved for use on March 30, 2024.</p>]]></description>
         <enclosure url="https://images.pexels.com/photos/8217290/pexels-photo-8217290.jpeg" />
         <pubDate>2024-09-22 16:32:26 UTC</pubDate>
         <guid>https://padlet.com/rmarsh6/rejoyn/wish/3131742115</guid>
      </item>
      <item>
         <title>Using Rejoyn</title>
         <author>rmarsh6</author>
         <link>https://padlet.com/rmarsh6/rejoyn/wish/3131744425</link>
         <description><![CDATA[<p>Rejoyn's core functionality includes the Emotional Faces Memory Task (EFMT), a cognitive task aimed at helping users balance brain activity by identifying and recalling emotional expressions. The app requires less than two hours of engagement per week over a six-week treatment course, making it a low-burden intervention for patients.</p>]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2777220244/c2beb551d86e1f524fa62eccd27923d5/rejoyn.jpg" />
         <pubDate>2024-09-22 16:36:14 UTC</pubDate>
         <guid>https://padlet.com/rmarsh6/rejoyn/wish/3131744425</guid>
      </item>
      <item>
         <title>Video on using Rejoyn</title>
         <author>rmarsh6</author>
         <link>https://padlet.com/rmarsh6/rejoyn/wish/3131749879</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://www.youtube.com/watch?v=6eiZdoXtrGQ" />
         <pubDate>2024-09-22 16:43:32 UTC</pubDate>
         <guid>https://padlet.com/rmarsh6/rejoyn/wish/3131749879</guid>
      </item>
      <item>
         <title>Pros</title>
         <author>rmarsh6</author>
         <link>https://padlet.com/rmarsh6/rejoyn/wish/3131770149</link>
         <description><![CDATA[<ul><li><p>First FDA-cleared app for treating MDD as adjunct to antidepressants.</p></li><li><p>Easy access via smartphones, making it more convenient for users.</p></li><li><p>Includes innovative working memory exercises targeting emotional material, potentially improving MDD symptoms.</p></li><li><p>Offers brief CBT lessons, personalized reminders, and messages.</p></li><li><p>Safe to use with no significant safety incidents in trials.</p></li><li><p>Adds to the landscape of digital therapeutic options, particularly for MDD.</p></li><li><p>Could help improve treatment adherence and engagement through regular reminders and interactions.</p></li></ul>]]></description>
         <enclosure url="https://pixabay.com/get/g3a791c3eeaabad8a08866427d8c0ddcbb1c07309d918c887e149e6aa5018980383c629970b2d20ba1652a338f03333a7.jpg" />
         <pubDate>2024-09-22 17:11:35 UTC</pubDate>
         <guid>https://padlet.com/rmarsh6/rejoyn/wish/3131770149</guid>
      </item>
      <item>
         <title>Cons</title>
         <author>rmarsh6</author>
         <link>https://padlet.com/rmarsh6/rejoyn/wish/3131770516</link>
         <description><![CDATA[<ul><li><p>Clinical trial results showed no statistically significant improvement over placebo.</p></li><li><p>Uncertain insurance coverage; out-of-pocket costs may limit accessibility.</p></li><li><p>Tested on a narrow subset of patients (e.g., excluding treatment-resistant depression, bipolar disorder, suicidal patients).</p></li><li><p>Questions about the actual active mechanism, possibly influenced by the "digital placebo effect."</p></li><li><p>Requires physician prescription, so it doesn’t fully reduce the cost or barriers to access.</p></li><li><p>Digital therapeutic market has a history of difficulties securing insurance reimbursement.</p></li></ul>]]></description>
         <enclosure url="https://dailymontanan.com/wp-content/uploads/2021/03/259bb77f-f485-4800-81e9-0e3e0f689559.jpeg" />
         <pubDate>2024-09-22 17:12:12 UTC</pubDate>
         <guid>https://padlet.com/rmarsh6/rejoyn/wish/3131770516</guid>
      </item>
      <item>
         <title>Strengths</title>
         <author>rmarsh6</author>
         <link>https://padlet.com/rmarsh6/rejoyn/wish/3131779537</link>
         <description><![CDATA[<p><strong>Angelica - Analytical:</strong> She will reinforce my ability to analyze situations and make data-driven decisions. Having another analytical thinker ensures that the team thoroughly evaluates the innovation.</p><p><strong>David - Deliberative:</strong> David will bring caution and careful consideration to decisions, ensuring that risks are thoroughly assessed, which pairs well with my problem-solving (Restorative) and detail-oriented (Analytical) strengths.</p><p><strong>Amelia – Adaptability: </strong>Amelia’s adaptability will help the team remain flexible and responsive to changing conditions, complementing my focus by providing balance when flexibility is needed.</p><p>I<strong>saac – Ideation: </strong>Isaac’s ability to generate creative ideas will be useful for brainstorming innovative approaches, balancing out my analytical and goal-driven mindset with fresh perspectives.</p><p><strong>Randall – Responsibility: </strong>Randall will ensure that tasks are completed with accountability. His sense of responsibility will align well with my Achiever and Focus strengths, ensuring that the team stays on track and follows through on commitments.</p><p><strong>My strengths:</strong> My strengths will significantly contribute to the team's success by driving productivity and ensuring that we stay on track to meet our goals. As an <strong>Achiever</strong>, I am goal-oriented and committed to getting things done, which will help maintain momentum and push the team forward. My <strong>Focus</strong> allows me to keep the team aligned with our objectives, avoiding distractions and ensuring we stay on course. The <strong>Relator</strong> strength enables me to foster deep, trusting relationships, enhancing collaboration and communication among team members. As someone who is <strong>Restorative</strong>, I naturally enjoy identifying problems and finding solutions, which will be valuable in addressing challenges that arise during the project. Lastly, my <strong>Analytical</strong> mindset ensures that decisions are based on data and evidence, bringing logic and structure to our problem-solving and decision-making processes. Together, these strengths will help create a productive, collaborative, and solution-oriented team environment.</p>]]></description>
         <enclosure url="https://pixabay.com/get/gcc5cb4a379a0335d3c4120fd8e2357012051043d59d4ea40e31117a43aa98827f8d6b37bc84d6ada8a5a9e6ce0ab7aa3.jpg" />
         <pubDate>2024-09-22 17:26:04 UTC</pubDate>
         <guid>https://padlet.com/rmarsh6/rejoyn/wish/3131779537</guid>
      </item>
      <item>
         <title>References</title>
         <author>rmarsh6</author>
         <link>https://padlet.com/rmarsh6/rejoyn/wish/3132018272</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2777220244/19aa23fb2d2601037c6ea6309b51f049/refpadlet.docx" />
         <pubDate>2024-09-22 23:59:17 UTC</pubDate>
         <guid>https://padlet.com/rmarsh6/rejoyn/wish/3132018272</guid>
      </item>
      <item>
         <title>My opinion</title>
         <author>rmarsh6</author>
         <link>https://padlet.com/rmarsh6/rejoyn/wish/3132043538</link>
         <description><![CDATA[<p>I support the Rejoyn app as an innovative, accessible tool for treating major depressive disorder (MDD), especially as an adjunct to traditional antidepressant therapy. While trial results did not show a statistically significant difference from placebo, both groups improved, suggesting the app can still be effective in managing symptoms. With no safety concerns and features like CBT lessons, personalized reminders, and working memory exercises, Rejoyn can enhance patient engagement and complement clinician care. Its FDA clearance and potential to increase access to mental health treatment make it a valuable option in the evolving field of digital psychiatry.</p>]]></description>
         <enclosure url="https://pix4free.org/assets/library/2021-05-25/originals/potential.jpg" />
         <pubDate>2024-09-23 00:25:20 UTC</pubDate>
         <guid>https://padlet.com/rmarsh6/rejoyn/wish/3132043538</guid>
      </item>
   </channel>
</rss>
